Compare Hershey Co (HSY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs 10X Genomics Inc — how do they compare? Hershey Co trades at $183 (market cap $36.56B), while 10X Genomics Inc trades at $57.7 (market cap $7.61B). The key difference: Hershey Co is far larger — about 4.8× 10X Genomics Inc's market cap, and Hershey Co pays a 3.19% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| HSY | TXG | |
|---|---|---|
Market Cap | $36.56B | $7.61B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $58.57 |
52-Week Low | $162.31 | $11.34 |
Enterprise Value | $41.70B | $7.14B |
Dividend Yield | 3.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $183.19, up 0.24% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates by 33% and revenue growth of 4.5-5% guidance. Recent earnings show significant margin recovery to 45.3% as cocoa prices decline, supporting the stock's premium valuation at 24.86 P/E. Analyst consensus price target of $196.78 suggests 7.4% upside potential from current levels.
HSY presents a compelling investment case with improving fundamentals, dividend growth resumption, and margin expansion. However, risks include volume declines in salty snacks, competitive pressures, and potential cocoa price volatility. The stock's current technical overbought condition near resistance at $184 warrants caution despite positive earnings momentum and institutional support.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
